QuidelOrtho [QDEL] vs Enovis [ENOV] Detailed Stock Comparison
QuidelOrtho
NASDAQ
Loading...
Enovis
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: QuidelOrtho wins in 10 metrics, Enovis wins in 8 metrics, with 0 ties. QuidelOrtho appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | QuidelOrtho | Enovis | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -0.91 | -2.11 | Enovis |
| Price-to-Book Ratio | 0.63 | 0.70 | QuidelOrtho |
| Debt-to-Equity Ratio | 100.33 | 56.75 | Enovis |
| PEG Ratio | -0.01 | -0.02 | Enovis |
| EV/EBITDA | 7.58 | 8.57 | QuidelOrtho |
| Profit Margin (TTM) | -17.01% | -37.80% | QuidelOrtho |
| Operating Margin (TTM) | -0.73% | 2.41% | Enovis |
| EBITDA Margin (TTM) | N/A | 2.41% | N/A |
| Return on Equity | -15.64% | -28.25% | QuidelOrtho |
| Return on Assets (TTM) | 1.36% | 0.89% | QuidelOrtho |
| Free Cash Flow (TTM) | $-112.10M | $-67.21M | Enovis |
| 1-Year Return | -38.01% | -31.70% | Enovis |
| Price-to-Sales Ratio (TTM) | 0.64 | 0.83 | QuidelOrtho |
| Enterprise Value | $4.39B | $3.11B | QuidelOrtho |
| EV/Revenue Ratio | 1.60 | 1.42 | Enovis |
| Gross Profit Margin (TTM) | 44.78% | 59.29% | Enovis |
| Revenue per Share (TTM) | $41 | $39 | QuidelOrtho |
| Earnings per Share (Diluted) | $-6.84 | $-14.95 | QuidelOrtho |
| Beta (Stock Volatility) | -0.03 | 1.81 | QuidelOrtho |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
QuidelOrtho vs Enovis Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| QuidelOrtho | 8.73% | 7.60% | 9.24% | -7.55% | -33.51% | -38.06% |
| Enovis | 6.58% | 6.40% | 15.42% | -2.87% | -27.77% | -29.03% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| QuidelOrtho | -38.01% | -66.00% | -82.88% | 36.43% | 129.63% | 226.70% |
| Enovis | -31.70% | -39.89% | -45.63% | -53.03% | 39.98% | -10.88% |
Performance & Financial Health Analysis: QuidelOrtho vs Enovis
| Metric | QDEL | ENOV |
|---|---|---|
| Market Information | ||
| Market Cap | $1.77B | $1.81B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 911,915 | 961,957 |
| 90 Day Avg. Volume | 1,383,058 | 1,416,196 |
| Last Close | $27.90 | $31.44 |
| 52 Week Range | $22.05 - $49.45 | $25.47 - $49.83 |
| % from 52W High | -43.58% | -36.91% |
| All-Time High | $306.72 (Aug 03, 2020) | $129.72 (Jun 09, 2014) |
| % from All-Time High | -90.90% | -75.76% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.04% | 0.08% |
| Quarterly Earnings Growth | -0.04% | 0.08% |
| Financial Health | ||
| Profit Margin (TTM) | -0.17% | -0.38% |
| Operating Margin (TTM) | -0.01% | 0.02% |
| Return on Equity (TTM) | -0.16% | -0.28% |
| Debt to Equity (MRQ) | 100.33 | 56.75 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $41.25 | $45.11 |
| Cash per Share (MRQ) | $2.25 | $0.77 |
| Operating Cash Flow (TTM) | $200.40M | $188.06M |
| Levered Free Cash Flow (TTM) | $410.48M | $65.68M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | $0.00 |
Valuation & Enterprise Metrics Analysis: QuidelOrtho vs Enovis
| Metric | QDEL | ENOV |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -0.91 | -2.11 |
| Forward P/E | 9.81 | 10.01 |
| PEG Ratio | -0.01 | -0.02 |
| Price to Sales (TTM) | 0.64 | 0.83 |
| Price to Book (MRQ) | 0.63 | 0.70 |
| Market Capitalization | ||
| Market Capitalization | $1.77B | $1.81B |
| Enterprise Value | $4.39B | $3.11B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.60 | 1.42 |
| Enterprise to EBITDA | 7.58 | 8.57 |
| Risk & Other Metrics | ||
| Beta | -0.03 | 1.81 |
| Book Value per Share (MRQ) | $41.25 | $45.11 |
Financial Statements Comparison: QuidelOrtho vs Enovis
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | QDEL | ENOV |
|---|---|---|
| Revenue/Sales | $692.80M | $558.83M |
| Cost of Goods Sold | $349.50M | $226.61M |
| Gross Profit | $343.30M | $332.23M |
| Research & Development | $53.20M | $28.53M |
| Operating Income (EBIT) | $48.70M | $-42.91M |
| EBITDA | $154.20M | $27.14M |
| Pre-Tax Income | $-8.80M | $-57.35M |
| Income Tax | $3.90M | $-1.77M |
| Net Income (Profit) | $-12.70M | $-55.71M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | QDEL | ENOV |
|---|---|---|
| Cash & Equivalents | $127.10M | $38.46M |
| Total Current Assets | $1.26B | $1.22B |
| Total Current Liabilities | $1.05B | $477.42M |
| Long-Term Debt | $2.27B | $1.42B |
| Total Shareholders Equity | $3.00B | $2.62B |
| Retained Earnings | $123.10M | $-338.99M |
| Property, Plant & Equipment | $2.35B | $492.24M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | QDEL | ENOV |
|---|---|---|
| Operating Cash Flow | $41.90M | $-1.07M |
| Capital Expenditures | $-56.20M | $-43.26M |
| Free Cash Flow | $9.40M | $-44.86M |
| Debt Repayment | $-36.00M | $-15.44M |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | QDEL | ENOV |
|---|---|---|
| Shares Short | 6.59M | 6.88M |
| Short Ratio | 4.67 | 4.60 |
| Short % of Float | 0.16% | 0.18% |
| Average Daily Volume (10 Day) | 911,915 | 961,957 |
| Average Daily Volume (90 Day) | 1,383,058 | 1,416,196 |
| Shares Outstanding | 67.26M | 55.88M |
| Float Shares | 62.65M | 56.45M |
| % Held by Insiders | 0.01% | 0.02% |
| % Held by Institutions | 1.18% | 1.21% |
Dividend Analysis & Yield Comparison: QuidelOrtho vs Enovis
| Metric | QDEL | ENOV |
|---|---|---|
| Last 12-Month Dividend | N/A | $0.00 |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | $0.00 |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | $0.00 |
| Ex-Dividend Date | N/A | N/A |